Please login to the form below

Not currently logged in
Email:
Password:

ShangPharma hires Biogen exec

Art Taveras joins as chief scientific officer 

ShangPharma, Art Taveras ShangPharma has hired Biogen Idec's Dr Art Taveras as president and chief scientific officer.

Dr Taveras held several vice president roles at US-based biotech Biogen, including for small molecules drug discovery, chemistry R&D and CMC development.

He now moves to China to head science at ShangPharma, a clinical research organisation (CRO) which employs 2,000 scientists.

"His extensive leadership, strategic and technical experience at the highest levels in pharmaceutical drug discovery and development will be a great asset to the company as it strives to become the preferred small molecules and biologics drug discovery partner for biopharmaceutical companies,” said Michael Hui, chairman and CEO of ShangPharma.

Dr Taveras' career prior to joining Biogen includes senior positions at Alantos Pharmaceuticals and Schering-Plough.

28th October 2013

From: Research

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
OPEN Health

OPEN Health is a family of expert practices, working in partnership to drive positive change in healthcare communications & market...

Latest intelligence

Enabling market access through outcomes-based pricing
Outcomes-based pricing is a potential solution to create a link between product price and real-world outcomes, while at the same time facilitating patient access to new and innovative medicines....
Five companies 20 for 2020
20 for 2020 – Five pharma companies to watch
As a new decade gets into gear, we take a look at five pharma companies that have a lot riding on 2020...
The growing clinical importance of patient-reported outcomes (PROs)
Traditionally, the success or otherwise of medical treatments has been assessed by mortality or clinical assessments of health. However, patient self-reports of health are increasingly seen as central to the...

Infographics